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Abstract
Introduction: The traditional staging system is inadequate to identify those patients with stage II colorectal cancer (CRC) at
high risk of recurrence or with stage III CRC at low risk. A number of gene expression signatures to predict CRC prognosis
have been proposed, but none is routinely used in the clinic. The aim of this work was to assess the prediction ability and
potential clinical usefulness of these signatures in a series of independent datasets.
Methods: A literature review identified 31 gene expression signatures that used gene expression data to predict prognosis
in CRC tissue. The search was based on the PubMed database and was restricted to papers published from January 2004 to
December 2011. Eleven CRC gene expression datasets with outcome information were identified and downloaded from
public repositories. Random Forest classifier was used to build predictors from the gene lists. Matthews correlation
coefficient was chosen as a measure of classification accuracy and its associated p-value was used to assess association with
prognosis. For clinical usefulness evaluation, positive and negative post-tests probabilities were computed in stage II and III
samples.
Results: Five gene signatures showed significant association with prognosis and provided reasonable prediction accuracy in
their own training datasets. Nevertheless, all signatures showed low reproducibility in independent data. Stratified analyses
by stage or microsatellite instability status showed significant association but limited discrimination ability, especially in
stage II tumors. From a clinical perspective, the most predictive signatures showed a minor but significant improvement
over the classical staging system.
Conclusions: The published signatures show low prediction accuracy but moderate clinical usefulness. Although gene
expression data may inform prognosis, better strategies for signature validation are needed to encourage their widespread
use in the clinic.
Citation: Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Sole´ X, et al. (2012) Clinical Value of Prognosis Gene Expression Signatures in Colorectal
Cancer: A Systematic Review. PLoS ONE 7(11): e48877. doi:10.1371/journal.pone.0048877
Editor: Wayne A. Phillips, Peter MacCallum Cancer Centre, Australia
Received May 30, 2012; Accepted October 2, 2012; Published November 7, 2012
Copyright:  2012 Sanz-Pamplona et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the European Commission grant FP7-COOP-Health-2007-B HiPerDART. Also the Instituto de Salud Carlos III grants (FIS
PI08/1635, FIS PI08/1359 and FIS PI09-01037), CIBERESP CB07/02/2005, the Spanish Association Against Cancer (AECC) Scientific Foundation, and the Catalan
Government DURSI grant 2009SGR1489. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: v.moreno@iconcologia.net
. These authors contributed equally to this work.
Introduction
Colorectal cancer (CRC) is the third most common cancer
worldwide and the second leading cause of cancer death. During
the last decades, incidence has been increasing, while mortality has
slowly been decreasing [1]. A remarkable feature of CRC is the
difference in prognosis of the early and late stages of the disease:
stage I and II have moderate risk of relapse after surgical resection,
whereas patients with stage III have a higher chance of recurrence
[2]. Recognized clinical risk factors for recurrence are emergency
presentation, poorly differentiated tumor, depth of tumor invasion,
and adjacent organ involvement (T4) [3–5]. However, these
factors are insufficient to identify those patients with stage II CRC
at high risk of recurrence and posterior metastasis or those patients
with stage III CRC at low risk [6], leading to potential under-
treatment or over-treatment [3].
Colon cancer metastasis is a tightly regulated process that
requires aberrations in gene expression allowing cancer cells to
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progress through various steps until they colonize a distant organ
[7]. Probably the alterations necessary for recurrence are already
present in the primary colon carcinoma, which should allow
identifying prognostic signatures [8–10]. Gene-expression profil-
ing-based assays have been successful as prognostic tool in breast
cancer [11,12]. However, no signature has been adopted in
routine clinical practice in CRC despite a large number of gene
expression profiling studies on prognosis have been performed.
The aim of this work was to test the predictive ability of these
published signatures as prognostic markers in a significant number
of independent datasets, in order to understand their strengths and
weakness and identify if any of them can be used clinically to guide
decisions about adjuvant therapy for patients with stage II or III
CRC.
Materials and Methods
Published Gene Expression Signatures and Validation
Datasets
A systematic literature review was performed to identify studies
that used gene expression data to predict prognosis in CRC [13].
The search was based on the PubMed database and was restricted
to recent papers to increase validity (from January 2004 to
December 2011). Files S1–S2, Table S1 and Figure 1 detail the
selection protocol and PRISM checklist. Articles that provided a
list of differentially expressed genes in primary tumor samples
associated with CRC prognosis were included in our study. We
indistinctly refer to these lists of genes as ‘signatures’ or ‘profiles’.
Studies based on tissue microarray and those that exclusively were
focused on differences between stages or between primary tumor
and metastases were excluded. The studies finally included for
analysis are described in Table 1 [14–43]. Publicly available
datasets with whole-genome gene expression measures in CRC
primary tumor samples were identified and downloaded from
GEO [44] and ArrayExpress [45] microarray data repositories
(Tables 2 and 3). Pre-processed series matrixes originally provided
by the authors were used in our analysis.
Because different platforms and feature identifiers were used in
signatures and gene expression datasets, a translation into the
official Gene Symbol was done in order to have a common
annotation. This translation was performed using the Universal
Protein Resource annotation database [46], the online repository
of HUGO Gene Nomenclature Committee [47] and the chip
annotation files from the Affymetrix web site [48]. Unavoidably,
no match was found for some features in some datasets and they
were lost for subsequent analysis (File S3).
Statistical Analysis
Since follow-up time was not available for most of the datasets, a
binary outcome was defined as a prognosis status (Table 2).
Whenever possible, a minimum of three years of follow up was
required for patients without tumor recurrence. Nevertheless, two
datasets with no follow up information were included (GSE5206
and GSE10402) to increase the sample size. Stage IV individuals
were included in the analysis as recurrence events as it was
expected that the specific expression changes in poor prognostic
samples remain unaltered in the primary tumor once the
metastases has occurred. When data was available, subgroup
analysis were performed according to stage and microsatellite
instability status (MSS/MSI).
Each signature’s ability to predict prognosis was independently
tested in each dataset with a binary classification approach using
the Random Forest ensemble classifier (RF) [49,50]. Forests were
grown with a high number of trees (5.000) in order to assure out-
of-bag error convergence. The minimum size of terminal nodes
was set to one. For signatures evaluation, accuracy measures were
computed from a 10-fold cross-validation (10CV) process in which
partitions were stratified based on outcome. Nested in this process,
the number of candidate variables at each split was selected to
minimize the out-of-bag error. As suggested in [51], sub-sampling
was carried out without replacement and using the same number
of observations in each prognosis group (0.632 times frequency of
the smallest group). Due to lack of balance in outcome groups in
some datasets, RF showed a trend to preferably classify into the
most frequent group. To correct this artifact, the classification vote
cutoff was modified according to the corresponding prognosis
group frequencies. All these analyses were performed using the R
package randomForest [52].
To confirm our results, a radial kernel Support Vector Machine
(SVM) based classifier was also used [53,54]. Due to unbalance,
the same artifact described above was observed when applying the
standard SVM classifier. So, we tried to correct it using an under-
sampling strategy as follows [55]: i) select all samples from the less
frequent group; ii) randomly select the same number of samples
from the more frequent group; iii) repeat the process 25 times; iv)
define the predicted labels using the outcome group frequencies as
vote proportion cutoff for the classification rule. A 10CV process
was carried out to compute accuracy measures with a nested
10CV for parameter tuning, both of them stratified by outcome
groups. A wide range of values for cost and radial kernel
parameters were evaluated during the tuning process (20
equidistant values from 0.001 to 1.000 in logarithm scale; 11
equidistant values ranging 0.056p to 206p, being p the number of
features in each case). All these analysis were conducted with the R
package svmpath [56].
The Matthews Correlation Coefficient (MCC) [57] was chosen
as measure of classification accuracy [58]. This index combines
test sensitivity and specificity. It ranges from 21 to 1 and its
interpretation is similar to the Pearson’s correlation coefficient. In
the context of a classification problem it is expected that MCC
ranges from 0 (no prediction ability at all) to +1 (perfect prediction)
with negative values near zero possibly occurring in random
classifiers due to sample variability. MCC values lower than 0.3
can be considered as indicative of low predictive value as they
correspond to less than 65% accuracy in balanced data.
Sensitivity, specificity and overall accuracy rates were also
computed for interpretation purposes.
The potential usefulness of the signatures on clinical practice
was evaluated by means of the positive and negative likelihood
ratios (LR+, LR-) and the predicted positive and negative post-test
recurrence probabilities (PPTpr, NPTpr) in stage II and III
samples separately [59].
To summarize signature’s global performance, each of the
measures above was pooled across datasets to a unique index using
weights proportional to each dataset sample size. In order to
attenuate instability and bias in the cross-validation estimations,
datasets with less than 10 samples per group and those used in the
derivation of the profile in the original study were excluded from
these computations [60].
Significance of MCC, accuracy, sensitivity, specificity, LR+,
LR-, and differences of PPTpr and NPTpr were assessed using
null distributions based on 100.000 permutations. Computations
were done in the context of the theoretical framework for
permutation tests [61] as implemented in the R package coin
[62]. Intervals at 95% were built using the Bias Corrected and
Accelerated bootstrap (BCa) method with 5.000 resamples
stratified by prognosis group [63]. Empirical influence values
were estimated by the usual jackknife method. These calculations
Clinical Value of Signatures in Colorectal Cancer
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e48877
Clinical Value of Signatures in Colorectal Cancer
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e48877
were done using the R package boot [64]. In all cases, permutations
and resampling were performed directly on the predicted values
provided by the original models and no remodeling was done.
Since this strategy doesn’t take into account the dependence in
predictions implicitly imposed by the 10CV, it could potentially
retain some bias towards refusing null hypothesis in the statistical
tests when effects are small [65].
Results
Global Prognosis Performance of the Published Signatures
The literature search identified 29 papers reporting 31
signatures proposed as valid multi-gene tumor-outcome classifica-
tion tool (Table 1 and File S4). Almost all signatures were based on
microarray experiments with the exception of three signatures
obtained from PCR experiments (OC10, PL10, SC09). The
number of genes (signature size) ranged from 3 to 537.
Despite recommendations to provide raw data for microarray
experiments, training datasets were publicly available only for five
signatures: ST09, SM09, BD07, LN07, and VL10. Six additional
gene expression datasets with information about recurrence were
identified in GEO and ArrayExpress, for a total of 11 datasets
available for analysis (Table 2).
For all combinations of signatures and datasets, the MCC and
the corresponding p-value was computed. Figure 2 shows a color
map of the MCC values (details provided in File S5 and Figure
S1). As expected, the five signatures for which the training was
available showed significant association and a reasonable predic-
tive accuracy in their training datasets (black-highlighted cells at
the top left quadrant in the plot in Figure 2). For all these
signatures, MCC values were greater than 0.35 except for VL10
and dataset GSE17536 (MCC=0.32). Nevertheless, in the
independent datasets the performance was heterogeneous and
none of these five signatures could reproduce the degree of
predictive ability shown in the training datasets. When the
remaining 26 signatures (those without training set available) were
evaluated in the 11 datasets, similar results were obtained: some
signatures showed a significant association with patient outcome
but discrimination accuracy was low or moderate.
A global MCC was computed for each signature to summarize
their predictive ability across datasets (see Figure 2). Signatures
BT04 and KN11 emerged as the most predictive, both with a MCC
value of 0.25 (95% CI 0.19 to 0.31 and 0.19 to 0.30 respectively,
p-values ,105). Although nearly all the signatures reached the 5%
significance level in this pool estimate that combines 396 events in
1077 patients, only three signatures exceed a 0.20 global MCC.
The maximum value obtained for the proportion of correctly
classified cases was only 63% (BT04, sensitivity = 65% and
specificity = 61%) and it ranged from 52 to 61% for the remaining
profiles (Table 4, File S6).
To assess influence of the statistical methodology in the results, a
re-analyses was performed using an alternative method (SVM).
Although some variations in the signatures ranking of performance
were observed, similar results were obtained in terms of pooled
MCCs (Figure S2 and File S7).
Subgroup Analysis: Prognosis Performance of Published
Signatures Stratified by Stage or MSI Status
In order to assess the signatures’ performance in specific
subgroups of tumors, a stratified analysis was done according to
stage (stage II/stage III) and microsatellite instability status (MSS/
MSI), when this information was available (see Table 3). Datasets
contributing with less than 10 events were excluded.
Similar to the analysis including all samples, the performance of
the signatures was heterogeneous when stage II and III tumor
samples were analyzed separately (Figures S3 and S4). In the
pooled MCC, 17 signatures in stage II and 22 signatures in stage
III showed a significant association with prognosis (p-value,0.05).
Six signatures ranked in the top ten in both sub-analyses. The
MCC values obtained in stage II were much lower than those in
stage III. In stage II, the best global MCC were achieved by YM06
(MCC=0.21; 95%CI 0.11 to 0.31) and BT04 (MCC=0.20;
95%CI 0.10 to 0.31). In stage III, the two best signatures were
AJ08 (MCC=0.42; 95%CI 0.28 to 0.55) and VL10 (MCC=0.40;
95%CI 0.23 to 0.55). Table 4, Files S5, S6 and S7; and Figures S3,
S4, S5, S6, S7 and S8 contain more details.
MSI status information was only available for two datasets
(GSE13294 and GSE18088). In the analysis of MSS samples,
those MCC values that reached significance were moderate (0.19
to 0.38) and only three signatures showed association in both
datasets (p-value ,0.1). Regarding the MSI subset, only signature
HO09 provided a reasonably classification accuracy (MCC=0.30)
(File S5).
Potential Clinical Value of Signatures in Stage II and III
Tumors
Despite the low discrimination ability (shown by their pooled
MCC), the signatures could still have usefulness in clinical
practice. Briefly, a useful clinical test typically shows large LR+
and low LR- which translate into more discriminant post-test
event probabilities: high PPTpr and low NPTpr compared to the a
priori expected event proportion. So, even tests with low
discrimination ability according to pure statistic criteria could still
be useful in clinical practice if PPTpr and NPTpr are significantly
far enough from the probability expected in population when no
test is performed. To explore this issue, positive and negative post-
test probabilities of recurrence were calculated for stages II and
III. The prior recurrence risk in patients with CRC was assumed
to be 20% in stage II and 34% in stage III [4,66].
For the best signature in stage II (YM06), the post-test
recurrence probability for the high-risk group increased to 28%,
and for the low-risk group the prediction was 12% probability of
recurrence (16% absolute difference, Figure 3A). The best profile
in stage III (AJ08) increased to 56% the post-test probability of
recurrence for the high-risk group, while the post-test probability
was 18% for the low-risk group (38% absolute difference,
Figure 3B). Detailed results for all signatures are shown in Files
S6 and S7.
Discussion
The identification of molecular prognostic tools to facilitate
treatment decisions is an important step for individualized patient
therapy [10]. Here we report an exhaustive analysis of published
multi-gene prognostic classifiers in colorectal cancer, analyzing
their external validity in a large number of independent datasets
that total more than 1.000 patients. The present work is focused in
two objectives which are addressed by the two main parts of the
analysis: to evaluate the global performance of the signatures from
a statistical point of view, in which all stages were included, and to
Figure 1. PRISMA Diagram which depicts the flow of information through the different phases of the prognosis signatures studies
systematic review.
doi:10.1371/journal.pone.0048877.g001
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assess their potential clinical usefulness, restricted to stage II and
III CRC patients, by means of appropriate accuracy measures
(post-test probabilities).
A meta-analysis of gene expression profiles in stage II CRC has
been previously reported by Lu et al. [67]. In that study, promising
results were reported regarding predictive accuracy, but the
analysis was confined to the same datasets and predictions used in
the original studies. To our knowledge, our study is the first meta-
analysis in which prediction accuracy of many signatures is
measured in a large number of independent CRC samples to
assess external validity and their subsequently potential usefulness
in clinics.
In terms of global performance, our results indicate that in their
training dataset, most signatures showed a significant association
with prognosis and could reasonably predict the outcome.
However, none of the signatures performed satisfactorily when
the prediction ability was assessed in independent datasets. The
best pooled MCC was 0.25 (BT04), which should be considered a
low classification value. As a reference, stage provides an MCC of
0.23 (data not shown).
Next, we focused in specific performance of signatures in stage
II and III patients, who could benefit more of an accurate
prognosis prediction since adjuvant chemotherapy could be
tailored to their predicted recurrence risk. Although association
with outcome was observed for 17 signatures in stage II, their
predictive ability can only be considered poor from a statistical
point of view. Otherwise, MCC values in stage III were observed
to be near double those in stage II. Nevertheless, only eight
signatures achieved a 0.30 pooled MCC value, considered as
indicative of moderate predictive value.
Although poor results were observed in terms of classification
accuracy, almost all profiles (30) showed a significant association
with prognosis when tested in independent datasets (p-value
,0.05). Notice however that significant association only means
that a signature prediction is not completely random (MCC=0).
Association is not sufficient to be useful since, with enough sample
size, small effects can be significant. Better indicators of potential
usefulness than significance are magnitude of the sensitivity and
specificity or derived measures like the MCC or likelihood ratios,
Figure 2. Heatmap showing Matthews Correlation Coefficient (MCC) values for each signature in each dataset as result of analyses
with Random Forest. Rows correspond to signatures and columns to datasets. Last column shows a pooled MCC across datasets using sample size
as weights. Black lines delimit the first five signatures for which training datasets were available (cells highlighted in black). Cells representing
signatures and datasets used to validate them are highlighted in blue. Color scale represents the MCC values: the darker the color, the higher MCC
(see the legend). Negative values were collapsed to zero.
doi:10.1371/journal.pone.0048877.g002
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which measure the ability to correctly classify patients by their
outcome.
Despite these disappointing results according to pure statistic
criteria of discrimination ability, signatures might still be useful in
clinical practice if they provide additional risk stratification within
known sub-populations defined by relevant clinical variables. The
positive and negative post-test probabilities of recurrence were
calculated stratified by stage to identify the degree of prognosis
discrimination beyond stage. The results for the best signature in
stage II samples (YM06) moderately modified the 20% a priory
recurrence probability to a 28% and 12% for the positive and
negative post-test result, respectively. This discriminating ability is
not completely satisfactory given the large false negative and
positive rates that it would induce, but might contribute to the
identification of stage II patients at high risk for recurrence leading
to a better indication of adjuvant chemotherapy [6]. The best
signature for stage III patients (AJ08) resulted in a larger
discrimination of risk groups, with a difference between positive
and negative post-test probabilities of 38%. However, the low risk
group still showed a relatively large recurrence probability of 18%,
too high to recommend avoiding adjuvant chemotherapy as it is
indicated nowadays.
Potential explanations for these modest results must be
considered. From a statistical point of view, technical problems
such as low sample size, the number of genes included in the
classifier, translation between platforms or cohort heterogeneity,
among others, have been reported as potential explanations for the
lack of clinical translation of genomic classifiers (see references
[68,69,70]). In our case and for some signatures, only association
with prognosis was reported in the original work, thus the authors
implicitly recognized poor classification ability. In those profiles
that were reported to be highly discriminative, the reason could be
a poor control of over-fitting in the training methodology, since
external validation was performed only in three studies and the test
samples sizes were small (JG08, WN10 and YM06, see Table 1).
The need to map probes to genes for signatures that had used
different platforms may also have affected the results, since it is
known that even multiple probes of the same gene in the same
platform may show important variability. We could not detect,
however, that platform had a relevant effect in the MCC
estimates.
Low availability of information and heterogeneity in clinical
data is inherent to the use of public datasets and this is a major
impediment for repeatability and integration of published micro-
array studies [71]. Datasets differ in patient characteristics,
inclusion criteria and outcome definitions. A precise and
homogeneous definition of the outcome across datasets would be
desirable in order to obtain an accurate estimation of the
signatures’ prognosis ability. Nevertheless, heterogeneity of
datasets allows for a more pragmatic analysis and the estimates
should reflect the expected results when profiles were used in real
practice, since hospital settings are also heterogeneous. Since
different outcomes are supposed to be highly correlated [72], we
decided to prioritize a minimum sample size availability to get
more precise estimates and avoid uncertainty introduced by
datasets with less than 10 events [60]. The requirement of a three
years minimum follow up also allowed maximizing sample size
and was supported by the literature: it has been described that
most of these relapses occur within 3 years after surgery and it is
recommended to be used as endpoint in adjuvant clinical trials
[73]. Therapy regimen followed by treated patients was not
considered, as this information was not available for most of the
analyzed datasets.T
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Patients diagnosed at stage IV were included and considered
recurrent events to assess global performance. This implicitly
assumes that the molecular changes playing a driver role to disease
relapse remain unchanged in primary tumor after recurrence has
occurred. Though this underlying hypothesis could be question-
able, it was shared by many of the original studies analyzed that
included stage IV subjects in their training and test datasets (AJ08,
BT04, EC05, HO09, JS09, LN07G, LN07NZ, PL10, SC09, SL10,
SM09, ST09, VL10 and YM06).
From a biological perspective, this moderate prognosis ability
could be explained by heterogeneity in tumor cell populations that
might dilute the prognosis molecular signal. It is well known that
CRC tumors are composed not only by tumor epithelial cells but
also by cancer-associated stromal fibroblasts (CAFs), endothelial
cells or inflammatory cells, among others [74]. Moreover, those
cancer cells at the invasive front are different from those in the
main tumor mass [75]. The problem of the tumor bulk
heterogeneity can be overcome by isolating specific cells popula-
tions by laser microdissection technology [76]. In this regard, one
out of the eleven sample sets used in this study (GSE12945) used
this technique to specifically hybridize RNA from tumor cells.
Surgical specimens from other sample sets were reviewed by a
pathologist to assess a minimum tumor content of 80% (GSE5206,
GSE18088, E-MEXP-1245). However, we did not observe
significant differences in signatures performance regarding the
tumor-cell enrichment method used.
The gene lists included in this study had little overlap: out of
1.530 genes reported in the 31 profiles, only two were shared by
four signatures; 10 were shared by three signatures and 102 were
present in two profiles. This result was not unexpected, since it has
previously been reported [77,78]. The lack of gene overlap is
generally interpreted as if each signature is random sampling of a
small subset of genes from a larger signature that represent the
involved pathways [79,80].
Colon and rectum tumors have been included indiscriminately
in this work since in a previous report we showed that no
significant differences exist between colon and rectum tumors at
transcriptomic level [81]. However, this decision might explain
some of the poor performance of the signatures, since it is known
that surgery quality is an important prognostic factor in rectal
cancer and less important in colon [82]. In the data used in this
work, no significant association was found between prognosis and
tumor location (data not shown).
The choice of the statistical tools for analyses was an important
matter. The intention of this analysis was to test the performance
of published prognostic signatures in independent datasets rather
than trying to reproduce them using the original methodology. In
this context, Random Forest arises as an efficient method that
performs very well compared with other competitors [49,83]. As
expected, the signatures tested in their training dataset showed the
highest accuracy. Moreover, we succeeded in reproducing the
validation results of three out of the five signatures for which data
was available (SM09, VL10 and JS09). However, association with
prognosis was not observed for profile ST09 in dataset GSE12945,
and it was only observed in one out of the three independent
validation datasets that are included in this work for profile SL10,
although good performance was originally reported (see Table 1,
Figure 2 and File S5). A reason could be that the methodology we
used does not capture well the prognosis value of some signatures,
which might have been developed with more elaborated
algorithms to define the risk prediction in the original study.
Because this was a recognized limitation of this work, analyses
were redone using an alternative methodology (SVM), which
provided similar results (Figures S2, S5 and S6, File S7). In ST09
profile, a semi-supervised approach was used while in SL10 a
nearest-centroid approach was applied which was not properly
described in the paper. SL10 was developed in an Agilent platform
and the mapping of the probes to different validation platforms
used in the datasets might be an addition source of divergence.
Figure 3. Differences between positive and negative post-test
probabilities of recurrence and their 95% confidence interval
for stage II (A) and stage III (B). Prevalence probability of recurrence
for stage II and III were assumed to be 20 and 34% respectively.
Signatures are listed in decreasing order of post-tests probability
differences.
doi:10.1371/journal.pone.0048877.g003
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Although some works reported that simpler methods for
supervised learning in the context of high-dimensional molecular
data could perform equally than those used in this paper which are
more elaborated [84], we chose RF and SVM because they are
reported to be robust to over-fitting and the presence of noise, and
they capable to learn complex classification functions. These
properties are especially desirable in our study as we try to capture
the hypothetical prediction ability of signatures created with very
heterogeneous methodologies [49,50,52,53]. So, our choice of
these methodologies reflects our efforts in finding the prognosis
information reported in the original works, though we may have
failed in some complex signatures.
It is worth noting that two of the analyzed signatures correspond
to current available commercial test for CRC prognosis. Oncotype
DX was derived from OC10 profile [85] and, interestingly, the
reported risk estimations for strata in stage II in their validation
study [43] were similar to those obtained in our work
(PPTpr = 25% and 22%, NPTpr= 12% and 16% respectively).
The algorithm for risk estimation with Oncotype DX implies the
use of additional clinical information as tumor extent and
mismatch repair status, which substantially improves its risk
stratification. To our knowledge, no validation results for stage III
patients have been published yet. Coloprint test was derived from
SL10, which showed a low performance in our analysis, possibly
for the reasons discussed above.
The characteristics of the available test datasets could be other
reason of poor performance. Intriguingly, in some datasets (e.g.
GSE17537) the performance of signatures was better than for
others. This effect was not due to sample size neither tumor cell
enrichment: Datasets with the largest number of events
(GSE14333 and GSE13294) were not well classified by any of
the tested signatures, and datasets with high tumor cell content
showed uneven performance (e.g. GSE12945, GSE5206).
Conclusions
Although most of the published signatures of prognosis in CRC
tested in this analysis have shown significant statistical association
with prognosis, their ability to accurately classify independent
samples into high-risk and low-risk groups is limited. Thus, even
when prognosis differences exist in expression data, higher
accuracy is needed to consider a signature useful for the clinical
practice. Well-designed studies, with large sample size, and
preferably prospective are needed to accurately identify those
patients at risk of recurrence, especially among patients with stage
II CRC tumors.
Supporting Information
Figure S1 Boxplots showing signatures’ MCC values in each
dataset and pooled MCC. Dataset GSE2630 was excluded from
pooled analysis due to low sample size.
(PDF)
Figure S2 Heatmap showing Matthews Correlation Coefficient
values (MCC) for each signature in each dataset as result of
analyses with Support Vector Machine. Rows correspond to
signatures and columns to datasets. Last column shows a pooled
MCC across datasets using sample size as weights. Black lines
delimit the first five signatures for which training datasets were
available (cells highlighted in black). Cells representing signatures
and datasets used to validate them are highlighted in blue. Color
scale represents the MCC values: the darker the color, the higher
MCC (see the legend). Negative values were collapsed to zero.
(PDF)
Figure S3 Heatmap showing Matthews Correlation Coefficient
(MCC) in stage II tumors as result of analyses with Random
Forest. Empty columns are placed in case of no available data and
datasets with less than 10 events, which were excluded from
analyses.
(PDF)
Figure S4 Heatmap showing Matthews Correlation Coefficient
(MCC) in stage III tumors as result of analyses with Random
Forest. Empty columns are placed in case of no available data and
datasets with less than 10 events, which were excluded from
analyses.
(PDF)
Figure S5 Heatmap showing Matthews Correlation Coefficient
(MCC) in stage II tumors as result of analyses with Support Vector
Machine. Empty columns are placed in case of no available data
and datasets with less than 10 events, which were excluded from
analyses.
(PDF)
Figure S6 Heatmap showing Matthews Correlation Coefficient
(MCC) in stage III tumors as result of analyses with Support
Vector Machine. Empty columns are placed in case of no available
data and datasets with less than 10 events, which were excluded
from analyses.
(PDF)
Figure S7 Example of outcome association in stage II samples
using disease free survival information: Kaplan-Meier estimates for
risk groups predicted by signature YM06 in GSE13294 dataset
(Random Forest results).
(PDF)
Figure S8 Example of outcome association in stage III samples
using disease free survival information: Kaplan-Meier estimates for
risk groups predicted by signature AJ08 in GSE14333 dataset
(Random Forest results).
(PDF)
Table S1 Excluded papers by eligibility criteria in the literature
review.
(PDF)
File S1 Details on the prognosis signatures studies systematic
review containing inclusion and exclusion criteria at each step.
(PDF)
File S2 The 27 PRISMA checklist items corresponding to the
prognosis signatures studies systematic review.
(PDF)
File S3 Signatures translation results. Translation results for
each signature to the platforms of public datasets used in this work:
Affymetryx, Hs-OperonV2-vB2.2, Human 19 K Oligo array,
MWG 30 K Oligo set and Rosetta custom human 23 K array.
Translation was performed via Gene Symbol when necessary,
using the Universal Protein Resource annotation database, the
online repository of HUGO Gene Nomenclature Committee and
the chip annotation files from the Affymetrix official web site.
Signature: signature name; Platform: platform used to derive
the signature; Reported size: size of signature reported in the
original paper (genes or features); Extracted size: size of
signature after extraction from the original paper (genes or
features); Gene Symbols: size of signature in terms of official
Gene Symbol when translation was possible; Not found: number
of signature features not found in the platform; % not found:
percentage of signature features not found in the platform (respect
to extracted size); Platform features: signature size in the
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platform after translation. Signatures are listed in decreasing order
of % not found.
(XLS)
File S4 Signatures official Gene Symbols and overlapping.
Signatures Gene Symbol: signatures in terms of Gene Symbol.
For each signature, official Gene Symbols to which some of their
original feature was translated are listed. Translation was
performed using the Universal Protein Resource annotation
database, the online repository of HUGO Gene Nomenclature
Committee and the chip annotation files from the Affymetrix
official web site. Signatures overlap: official Gene Symbols
shared by four, three and two of the signatures used in this work.
List of no shared Gene Symbols (Genes in 1 signatures) is also shown.
(XLS)
File S5 Random Forest classification results. Random Forest
classification results for each signature and dataset are shown for
all, stage II, stage III, Microsatellite Stable and Microsatellite
instable samples analyses. MCC: Matthews Correlation Coeffi-
cient (MCC) and 95% confidence interval; p-value: permutation
p-value associated with MCC; Acc: accuracy rate; Sens:
sensitivity; Spec: specificity; No events/events: number of
samples with good and bad prognosis respectively. Last column
shows the same values for the pooled analyses across datasets using
sample size as weights.
(XLS)
File S6 Global performance of signatures for all, stage II and
stage III samples using Random Forest classifier. For each
signature, sample size used in the analysis (separately for good
and bad prognosis between brackets), pooled Matthews Correla-
tion Coefficients (MCC) with 95% confidence intervals, accuracy
rates, sensitivities and specificities are shown. For stage II and stage
III analyses, also positive and negative likelihood ratios, negative
and positive post-test probabilities, differences between post-test
probabilities and 95% confidence interval are reported. Signatures
are listed in decreasing order of MCC. Those with significant
MCC at 5% level are highlighted in bold letters.
(XLS)
File S7 Support Vector Machine classification results. Sheets
All samples, Stage 2 and Stage 3: Support Vector Machine
classification results for each signature and dataset are shown for
all, stage II and, stage III analyses sheets respectively. MCC:
Matthews Correlation Coefficient (MCC) and 95% confidence
interval; p-value: permutation p-value associated with MCC;
Acc: accuracy rate; Sens: sensitivity; Spec: specificity; No
events/events: number of samples with good and bad prognosis
respectively in that dataset. Sheets All samples global, Stage 2
global and Stage 3 global: Global performance results of
signatures for all, stage II and stage III samples using Support
Vector Machine are extended. Signatures are listed in decreasing
order of MCC. Those with significant MCC at 5% level are
highlighted in bold letters.
(XLS)
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